Article
Automating neoantigen selection for personalized cancer vaccine design
2026-07-01
Abstract excerpt
Advancements in immunogenomics and immuno-oncology have enabled the development of personalized cancer vaccines (PCVs) that target cancer cell-specific somatic variants. A subset of these variants produce neoantigens that, when presented on tumor cells by MHC molecules, have the potential to elicit a robust and specific immune response. To date, there are over one hundred interventional studies listed on clinical...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 11caf38f-bd37-588a-8e42-a8d46c67053e
- DOI
- 10.64898/2026.06.24.26356293
